Dr Pezaro is a medical oncologist with particular interests in prostate cancer and clinical and translational research. She trained in New Zealand and Australia and commenced consultant practice in 2009. After completing a basic science doctorate through the University of Melbourne, she spent two years working as a clinical trials fellow at the Royal Marsden NHS Foundation Trust, under the mentorship of Professor Johann de Bono. From 2013-2018 Dr Pezaro worked as a medical oncologist in Melbourne Australia, where she was actively involved in cooperative group research, served on national research advisory committees and was elected to the Economic Sub-Committee of the Pharmaceutical Benefits Advisory Committee. In 2019, Dr Pezaro began a five-year Senior Clinical Research Fellowship with Yorkshire Cancer Research.

A/Prof Andrew Weickhardt and Dr Ainsley Campbell discuss treatment options for newly diagnosed metastatic prostate cancer, with esteemed guest Professor Ian Davis. Andrew Weickhardt is a consultant medical oncologist with a major interest in genitourinary cancers. Andrew has a joint appointment between Austin Hospital and the Olivia Newton John Cancer Research Institute. He oversees the genitourinary clinical trials program at the Austin Hospital. He has published over 20 peer reviewed publications and his research on targeted therapies has been recognised with multiple awards including two American Society for Clinical Oncology Merit Awards. Ainsley Campbell is a medical oncologist and Director of Genetics at Austin Health based in Heidelberg, Victoria. Ainsley has an interest in GU oncology and cancer genetics. Professor Ian Davis is a medical oncologist and is Professor of Medicine and Head of the Eastern Health Clinical School, Monash University & Eastern Health, in Melbourne Australia. He is an NHMRC Practitioner Fellow. He holds honorary appointments with the Olivia Newton-John Cancer Research Institute (formerly Ludwig Institute for Cancer Research) and Austin Health, is an Associate Professor of the University of Melbourne, and Associate of the University of Sydney. His primary clinical interests are in urologic cancer and melanoma, and his primary research interests are in cancer immunology and the biology of urologic cancers.

Join Joseph Ischia, Amy Teh and Nick James as they discuss radiation to the prostate in metastatic prostate cancer. Dr Amy Teh is the Lead Regional Radiation Oncologist at the ICON Cancer Centre for NSW/ACT, a consultant Radiation Oncologist at the Sydney Adventist Hospital and a Clinical Senior Lecturer at the Sydney Medical School, The University of Sydney. A member of TROG and ANZUP Clinical Trials Group, Dr Teh is lead site-investigator for the RAVES, ENZARAD, DASL-HiCap prostate cancer trials at the Sydney Adventist Hospital and has led the Prostate Brachytherapy Program at the Sydney Adventist Hospital, and also the Radiation Oncology Research Committee Co-Chair for the ICON Cancer Centre. Professor James is Consultant in Clinical Oncology at the Queen Elizabeth Hospital Birmingham and Professor of Clinical Oncology at the University of Birmingham. Professor James is internationally renowned for his work in Urological Cancer, particularly on the ground-breaking STAMPEDE trial, which has been used to evaluate, to date, 10 different therapies for advanced prostate cancer in more than 10,000 men. He is a regular educational speaker at conferences worldwide, recently including the American Society of Clinical Oncology, European Society of Medical Oncology and European Association of Urologists Annual Meetings. Results from STAMPEDE with both first line docetaxel chemotherapy and abiraterone have shown that big survival gains can be made by using existing treatments in novel settings. These findings have been practice changing worldwide.

Sit back & relax as you listen to Joseph Ischia and Andrew Redfern discuss the similarities and differences in our understanding and management of breast vs prostate cancer. Andy Redfern is a Consultant Medical Oncologist with a special interest in both prostate and breast cancer. He is based at the South Metropolitan Health Service, as well as Clinical Academic Oncologist at the UWA Medical School, University of Western Australia and the current Clinical Head of the Cancer Division, Harry Perkins Institute of Medical Research. He is also Medical Director of Linear Clinical Research, Western Australia’s centre for early drug trials and is the State Lead Clinical for Breast Cancer overseeing services across the state. Proudly supported by Janssen

Prof Michael Hofman discusses radionuclide therapy as treatment for advanced prostate cancer with hosts Chris Hocking and Ann Mislang.

Part 2 sees Joseph Ischia chat with well-known leaders in the field of prostate cancer management.

Listen in to part 1 as Joseph Ischia unearths some gems of wisdom from leaders in the field of prostate cancer management.